首页> 外文期刊>Cancer and Clinical Oncology >Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique
【24h】

Detection of Anaplastic Lymphoma Kinase (ALK) gene in Non-Small Cell lung Cancer (NSCLC) By CISH Technique

机译:应用CISH技术检测非小细胞肺癌(NSCLC)中间变性淋巴瘤激酶(ALK)基因

获取原文
       

摘要

Background/Aim: Anaplastic Lymphoma Kinase (ALK) rearrangement has evaluated activity of NSCLC compared with other molecular subtypes (EGFR, KRAS). Many studies demonstrated that patients with?ALK rearrangement?positive NSCLC have improved with a good response rates and progression (free survival) when treated with either monotherapy or by a combination therapy compared with EGFR-mutated, KRAS/EGFR/ALK?wild type or KRAS-mutated. The aim of this study was to detect and study the signal pattern of normal ALK and compare it to that of mutated ALK with gene rearrangement in cases of non-small cell lung cancer and Inflammatory conditions by implementing the CISH technique. In addition to correlate ALK signal pattern with the histopathological type and grade as well as the age and sex of the patients. Materials & Methods: Forty patients with NSCLC and Inflammatory diseases were enrolled in a comparative cross sectional study. The tissue blocks were sectioned on non-charged slides for the preparation of routine H&E staining. Positively charged slides were used for tissue sections prepared for chromogenic in situ hybridization procedure to detect ALK gene. Results: ALK gene signal break apart was detected in (18/20, 90%) of malignant cases; (0/20, 0%) of non-neoplastic lung lesions. There was a significant statistical difference in their distribution, p & 0.05. While There was no significant association between any disease status and sex P value = 1.000NS. The CISH test was 100% sensitive using negative score as a cutoff point and 90.9% specific. The score was divided into three levels that categorized the cases, so there were six cases in score one (1-32%), nine cases in score two (33-67%) and three cases in score three (68-100%). Conclusion: Detection of ALK rearrangement in the early diagnosis of NSCLC is highly sensitive and can save a lot of efforts in planning chemotherapy regimens. Results were very promising in identifying this mutation by a sensitive and highly specific test. The ALK gene rearrangement could be an early mutation and it is needed as an initiating step for the carcinogenesis process. The presence of a double gene mutation, however, could be the cause of a higher-grade cancer.
机译:背景/目的:与其他分子亚型(EGFR,KRAS)相比,间变性淋巴瘤激酶(ALK)重排评估了NSCLC的活性。许多研究表明,与EGFR突变型,KRAS / EGFR / ALK野生型或EGFR突变型相比,单一疗法或联合疗法治疗“ ALK重排阳性” NSCLC的患者具有良好的缓解率和进展(自由生存)。 KRAS突变。这项研究的目的是通过实施CISH技术检测和研究正常ALK的信号模式,并将其与具有基因重排的突变ALK进行比较,以进行非小细胞肺癌和炎症性疾病。除了使ALK信号模式与组织病理学类型和等级以及患者的年龄和性别相关之外。材料和方法:40名患有非小细胞肺癌和炎性疾病的患者参加了一项比较性横断面研究。将组织块在不带电的载玻片上切成薄片,以制备常规的H& E染色。将带正电荷的载玻片用于准备用于显色原位杂交程序以检测ALK基因的组织切片。结果:(18/20,90%)恶性肿瘤中检测到ALK基因信号断裂; (0/20,0%)非肿瘤性肺部病变。它们的分布存在显着的统计学差异,p <0。 0.05。虽然任何疾病状态与性别P值= 1.000NS之间均无显着关联。 CISH测试使用阴性评分作为临界点具有100%的敏感性,特异性为90.9%。该分数分为三个级别,按案例分类,因此,分数1中有6例(1-32%),分数2中有9例(33-67%),分数3中有3例(68-100%) 。结论:在NSCLC的早期诊断中检测ALK重排非常灵敏,可以节省计划化疗方案的大量工作。通过灵敏且高度特异性的测试鉴定该突变的结果非常有希望。 ALK基因重排可能是早期突变,需要作为致癌过程的起始步骤。但是,双基因突变的存在可能是导致更高级别癌症的原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号